News | March 25, 2026
Siemens Healthineers expands radiotherapy beyond cancer, targets osteoarthritis pain
The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge
The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
CIVCO RT will also display its recent innovations focusing on improving patient comfort and outcomes
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
Hansoh Pharma will receive an upfront payment in the low double-digit millions
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Subscribe To Our Newsletter & Stay Updated
